PharmAI GmbH news

PharmAI attends the  XXVll EFMC International Symposium on Medicinal Chemistry held in Nice, France from September 4-8 2022. We are excited to be part of this meeting and showcase our technology at exhibition booth #30.

We are looking forward to the European Biotech & Pharma Virtual Partnering Conference, September 27-30, 2021. During the conference, we meet Japanese pharma companies and will show how PharmAI’s ground-breaking technology helps to accelerate the drug discovery process.

PharmAI announced a partnership with NanoTemper Technologies, the most innovative producer of biophysical characterization devices. Together, they will zero in on one of the biggest roadblocks to quick drug development: Researchers have to comb through large amounts of data to find the right drug candidates. This process is an innovation killer, making it difficult for small laboratories to do drug research and even discouraging large pharmaceutical companies from going after rare diseases.</

Side effects of drugs can have fatal consequences. It is therefore important to detect these side effects at an early stage. This is exactly what a new method developed by the Dresden-based start-up PharmAI GmbH and its partner, 2bind GmbH from Regensburg, is making possible. The two companies’ method combines artificial intelligence with highly efficient biophysical testing. The challenge of early side effect detection – which was previously similar to finding a needle in a hayst